Results 161 to 170 of about 7,856 (243)

CFTR modulators partially restore the epithelial interferome in Aspergillus infection to improve clinical outcome. [PDF]

EBioMedicine
Laverty SL, Felton I, Casey M, Hopwood B, Simmonds N, Armstrong-James D, Shah A, Kelleher P.   +7 more
europepmc   +1 more source

L467F;F508del Complex Allele in a Heterozygous State with CFTRdele2,3: What to Expect from CFTR Modulators? [PDF]

Int J Mol Sci
Kondratyeva E, Efremova A, Melyanovskaya Y, Krasnova M, Milovanov M, Shchagina O, Stepanova A, Voronkova A, Sherman V, Kutsev S, Goldshtein D.   +10 more
europepmc   +1 more source

Breaking boundaries or a small piece of the puzzle: can CFTR modulators transform bronchiectasis care? [PDF]

ERJ Open Res
Graeber SY, Frost F.
europepmc   +1 more source

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review. [PDF]

Front Pediatr
Pietrzykowska A, Darmoń J, Szymocha K, Donocik W, Tarasiewicz M, Stadnik J, Jarosz-Chobot P.   +6 more
europepmc   +1 more source

Phosphatidylserine liposomes for <i>Mycobacterium abscessus</i> infections management in people with cystic fibrosis non-eligible for CFTR modulators. [PDF]

Front Immunol
Olimpieri T, Poerio N, Saliu F, Lorè NI, Ciciriello F, Ponsecchi G, Alghisi F, Cirillo DM, D'Andrea MM, Fraziano M.   +9 more
europepmc   +1 more source

Novel CFTR Modulators for Treating Cystic Fibrosis [PDF]

ACS Medicinal Chemistry Letters, 2021
openaire   +3 more sources

Evolving Cystic Fibrosis Care: Lung Immunology and Emerging Health Challenges in the Era of CFTR Modulators. [PDF]

Biomolecules
Parisi GF, Papale M, Pecora G, Presti S, Tosto M, Mulé E, Ornato V, Aloisio D, Leonardi S.   +8 more
europepmc   +1 more source

Effects of CFTR Modulators on <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis. [PDF]

Infect Dis Rep
Pescaru CC, Crișan AF, Marițescu A, Cărunta V, Marc M, Dumitrache-Rujinski Ș, Laitin S, Oancea C.   +7 more
europepmc   +1 more source

Research and development spending versus revenues after approval for CFTR modulators

Background: The high prices of CFTR modulators present barriers to access for people with cystic fibrosis (pwCF), especially those in low- and middle-income countries. Costs of research and development (R&D) are often cited as key drivers of drug pricing.
Hill, Andrew, Hennessy, Grace, Guo, Jonathan, Young, Benedict   +3 more
core  

CFTR Modulators for the Treatment of Chronic Obstructive Pulmonary Disease: The Jury Is Still Out! [PDF]

Am J Respir Crit Care Med
Regard L, Burgel PR.
europepmc   +1 more source